Challenges of New Approaches in Metastatic Merkel Cell Carcinoma
Open Access
- 12 May 2020
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (2), 501-507
- https://doi.org/10.1159/000507279
Abstract
Merkel cell carcinoma is a rare and aggressive cutaneous tumor, and the use of checkpoint inhibitors immunotherapy is a recent indication in its metastatic setting, both first and second line. However, the widespread use of immunotherapy is associated with an increase of acute and late immune-mediated adverse events. We present a case of an elderly fit patient with metastatic Merkel cell carcinoma treated with pembrolizumab who developed diabetic ketoacidosis, a severe immune-mediated adverse event. A multidisciplinary approach was crucial to overcome the life-threatening event. Even with early treatment stop, the patient had a significant and durable response to the treatment for 15 months. Meanwhile, a progressive pan-cerebellar syndrome emerged, possible due to a paraneoplastic syndrome with a negative onco-neuronal antibody panel, although an autoimmune etiology associated with immunotherapy could not be excluded. Unfortunately, the situation was irreversible and refractory to immunomodulatory treatment. Despite the unpredictable toxicity, it is important to note the efficacy profile, with a progression-free survival of 15 months, which is higher than the one reported in reference clinical trials in this setting.Keywords
This publication has 10 references indexed in Scilit:
- Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patientMedicine, 2018
- Diabetic ketoacidosis induced by a single dose of pembrolizumabThe American Journal of Emergency Medicine, 2018
- Autoimmune pancerebellitis associated with pembrolizumab therapyNeurology, 2018
- Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2018
- Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor TherapyMayo Clinic Proceedings: Innovations, Quality & Outcomes, 2018
- Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case ReportsWorld Journal of Oncology, 2018
- Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsOncotarget, 2016
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaThe New England Journal of Medicine, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guidelineEuropean Journal of Cancer, 2015